4D Molecular Therapeutics Business Summary

4D Molecular Therapeutics, Inc. (FDMT) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, development milestones, and research grants, with long-term value tied to potential royalties and product commercialization. The company operates through three primary therapeutic segments: Ophthalmology, led by its Phase 3 candidate 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME); Pulmonology, featuring 4D-710 for cystic fibrosis; and Cardiology. Its business model leverages the proprietary Therapeutic Vector Evolution platform to engineer optimized AAV vectors for targeted delivery. Within the competitive landscape, FDMT contends with gene therapy and retinal specialists such as MeiraGTx, EyePoint Pharmaceuticals, and Sarepta Therapeutics. FDMT distinguishes itself as a late-stage leader, positioning 4D-150 as a disruptive "backbone" therapy designed to replace frequent bolus injections in the $17 billion global anti-VEGF market. The company was co-founded by CEO and President David Kirn, M.D., a veteran biotech entrepreneur previously of IGNITE Immunotherapy and Jennerex, alongside Theresa Janke (Chief of Staff) and scientific pioneer David Schaffer, Ph.D. The leadership team was recently restructured in early 2026, with Katy Barglow, Ph.D., promoted to Chief Technical Officer to oversee the transition to commercial manufacturing, and Chris Simms serving as Chief Commercial & Business Officer. The executive suite is complemented by CFO Kristian Humer and CMO Julie Clark, M.D. FDMT’s board is chaired by former Gilead CEO John Milligan and recently added Glenn P. Sblendorio, the former CEO of IVERIC bio, following its multi-billion dollar acquisition. Notable institutional backing includes Viking Global Investors and a significant strategic partnership with Otsuka Pharmaceutical, which supports the company’s financial runway into the second half of 2028.